Tesamorelin
Also known as TH9507, Egrifta
A full-length GHRH analogue approved in the US for reducing excess abdominal fat in HIV-associated lipodystrophy, and studied for liver fat.
Approved drug substance
Size
3 options- Catalog no.
- TSM5
- Specification
- 5mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
Tesamorelin is a synthetic analogue of all 44 amino acids of human GHRH, with a trans-3-hexenoyl group added at the N-terminus to resist enzymatic degradation. It stimulates endogenous growth hormone secretion and raises IGF-1. Phase 3 trials in people with HIV and abdominal fat accumulation led to US approval in 2010 for that single indication. Later randomized studies examined its effect on liver fat and non-alcoholic fatty liver disease in the same population.
Class: Stabilized GHRH analogue
Mechanism of action
How the compound acts, as described in the literature.
Agonist at the pituitary GHRH receptor, stimulating pulsatile growth hormone secretion.
The N-terminal trans-3-hexenoyl modification protects against dipeptidyl peptidase-4 cleavage, extending activity.
Raised GH and IGF-1 increase lipolysis, with clinical trials showing preferential reduction of visceral rather than subcutaneous fat.
Studies also report reductions in liver fat, attributed to GH-mediated changes in hepatic lipid handling.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
2007
Phase 3 RCT
PMID 18057338Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J, et al. · N Engl J Med
In 412 patients with HIV and abdominal fat accumulation, visceral fat fell 15.2% with tesamorelin over 26 weeks versus a 5.0% rise with placebo; IGF-I rose 81%. More tesamorelin patients withdrew because of adverse events.
2014
Randomized controlled trial
PMID 25038357Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Stanley TL, et al. · JAMA
Over 6 months in 50 patients, tesamorelin reduced visceral fat and liver fat versus placebo. Fasting glucose rose at 2 weeks, but the change was not significant at 6 months.
2019
Randomized controlled trial
PMID 31611038Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Stanley TL, et al. · Lancet HIV
In people with HIV and fatty liver disease, tesamorelin reduced hepatic fat fraction compared with placebo over one year.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
It is approved in the US only for excess abdominal fat in HIV-associated lipodystrophy. Trials reported more adverse-event withdrawals than placebo and early rises in fasting glucose, and visceral fat reaccumulated after treatment stopped. Evidence outside HIV populations is limited.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| TSM5 | Tesamorelin | 5mg*10vials | 10 |
| TSM10 | Tesamorelin | 10mg*10vials | 10 |
| TSM20 | Tesamorelin | 20mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.